2023 ICD-10-CM Diagnosis Code Q85.1

New Call-to-action

Tuberous sclerosis

    2016 2017 2018 2019 2020 2021 2022 2023 Billable/Specific Code POA Exempt
  • Q85.1 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
  • The 2023 edition of ICD-10-CM Q85.1 became effective on October 1, 2022.
  • This is the American ICD-10-CM version of Q85.1 - other international versions of ICD-10 Q85.1 may differ.
Applicable To
  • Bourneville's disease
  • Epiloia
The following code(s) above Q85.1 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
  • Applicable To annotations, or
  • Code Also annotations, or
  • Code First annotations, or
  • Excludes1 annotations, or
  • Excludes2 annotations, or
  • Includes annotations, or
  • Note annotations, or
  • Use Additional annotations
that may be applicable to Q85.1:
  • Q00-Q99
    2023 ICD-10-CM Range Q00-Q99

    Congenital malformations, deformations and chromosomal abnormalities

    • Codes from this chapter are not for use on maternal records
    Type 2 Excludes
    • inborn errors of metabolism (E70-E88)
    Congenital malformations, deformations and chromosomal abnormalities
  • Q85
    ICD-10-CM Diagnosis Code Q85

    Phakomatoses, not elsewhere classified

      2016 2017 2018 2019 2020 2021 2022 2023 Non-Billable/Non-Specific Code
    Type 1 Excludes
    • ataxia telangiectasia [Louis-Bar] (G11.3)
    • familial dysautonomia [Riley-Day] (G90.1)
    Phakomatoses, not elsewhere classified
Approximate Synonyms
  • Tuberous sclerosis syndrome
Clinical Information
  • A genetic disorder in which benign (not cancer) tumors form in the kidneys, brain, eyes, heart, lungs, and skin. This disease can cause seizures, mental disabilities, and different types of skin lesions.
  • A triad of epilepsy, mental retardation, and angiofibromas of numerous organs with intracranial hamartomatous lesions involving subependymal nodules and cerebral cortical tubers (hence the name "tuberous sclerosis."
  • Autosomal dominant disease characterized principally by the presences of hamartomas of the brain, retina, and visera; clinical manifestations include mental retardation, seizures, and adenoma sebaceum of the face.
  • Autosomal dominant neurocutaneous syndrome classically characterized by mental retardation; epilepsy; and skin lesions (e.g., adenoma sebaceum and hypomelanotic macules). There is, however, considerable heterogeneity in the neurologic manifestations. It is also associated with cortical tuber and hamartomas formation throughout the body, especially the heart, kidneys, and eyes. Mutations in two loci tsc1 and tsc2 that encode hamartin and tuberin, respectively, are associated with the disease.
  • Hereditary disease characterized by seizures, mental retardation, developmental delay, and skin and ocular lesions. First signs usually occur during infancy or childhood but in rare cases may not occur until 2nd or 3rd decade.
  • Tuberous sclerosis is a rare genetic disease that causes noncancerous tumors to grow in the brain and other organs. Symptoms vary depending on the location of the tumors. Common symptoms include
    • skin problems, such as light patches and thickened skin
    • seizures
    • behavior problems
    • learning disabilities
    • mental retardation
    • kidney problems
    some people have signs of tuberous sclerosis at birth. In others it can take time for the symptoms to develop. In some people the disease is mild, while in others it causes severe disabilities. In rare cases, tumors in vital organs or other symptoms can be life-threatening. Tuberous sclerosis has no cure, but treatments can help symptoms. Options include medicines, educational and occupational therapy, dermabrasion, and surgery.
Present On Admission
POA Help
"Present On Admission" is defined as present at the time the order for inpatient admission occurs — conditions that develop during an outpatient encounter, including emergency department, observation, or outpatient surgery, are considered POA.
  • Q85.1 is considered exempt from POA reporting.
ICD-10-CM Q85.1 is grouped within Diagnostic Related Group(s) (MS-DRG v40.0):
  • 091 Other disorders of nervous system with mcc
  • 092 Other disorders of nervous system with cc
  • 093 Other disorders of nervous system without cc/mcc

Convert Q85.1 to ICD-9-CM

Code History
  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
  • 2022 (effective 10/1/2021): No change
  • 2023 (effective 10/1/2022): No change

Diagnosis Index entries containing back-references to Q85.1:
  • Bourneville's disease Q85.1
  • Disease, diseased - see also Syndrome
    • Bourneville Q85.1 (-Brissaud) (tuberous sclerosis)
    • Pringle's Q85.1 (tuberous sclerosis)
  • Epiloia Q85.1
  • Neurospongioblastosis diffusa Q85.1
  • Nevus D22.9
    ICD-10-CM Diagnosis Code D22.9

    Melanocytic nevi, unspecified

      2016 2017 2018 2019 2020 2021 2022 2023 Billable/Specific Code
    • multiplex Q85.1
  • Phakomatosis Q85.9
    - see also specific eponymous syndromes
    ICD-10-CM Diagnosis Code Q85.9

    Phakomatosis, unspecified

      2016 2017 2018 2019 2020 2021 2022 2023 Billable/Specific Code POA Exempt
    Applicable To
    • Hamartosis NOS
    • Bourneville's Q85.1
  • Pringle's disease Q85.1 (tuberous sclerosis)
  • Sclerosis, sclerotic
    • brain (generalized) (lobular) G37.9
      ICD-10-CM Diagnosis Code G37.9

      Demyelinating disease of central nervous system, unspecified

        2016 2017 2018 2019 2020 2021 2022 2023 Billable/Specific Code
      • tuberous Q85.1
    • tuberous Q85.1 (brain)
  • Syndrome - see also Disease
    • Bourneville Q85.1 (-Pringle)
  • Tuberous sclerosis Q85.1 (brain)

ICD-10-CM Codes Adjacent To Q85.1
Q84.6 Other congenital malformations of nails
Q84.8 Other specified congenital malformations of integument
Q84.9 Congenital malformation of integument, unspecified
Q85 Phakomatoses, not elsewhere classified
Q85.0 Neurofibromatosis (nonmalignant)
Q85.00 Neurofibromatosis, unspecified
Q85.01 Neurofibromatosis, type 1
Q85.02 Neurofibromatosis, type 2
Q85.03 Schwannomatosis
Q85.09 Other neurofibromatosis
Q85.1 Tuberous sclerosis
Q85.8 Other phakomatoses, not elsewhere classified
Q85.81 PTEN tumor syndrome
Q85.82 Other Cowden syndrome
Q85.83 Von Hippel-Lindau syndrome
Q85.89 Other phakomatoses, not elsewhere classified
Q85.9 Phakomatosis, unspecified
Q86 Congenital malformation syndromes due to known exogenous causes, not elsewhere classified
Q86.0 Fetal alcohol syndrome (dysmorphic)
Q86.1 Fetal hydantoin syndrome
Q86.2 Dysmorphism due to warfarin

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.